# Biweekly Meeting 1 - Week 1-2 Progress Summary

**Date:** December 19, 2025  
**Meeting Duration:** 1 hour  
**Participants:** Peter Ugonna Obi  
**Project:** Explainable AI for Diabetes Risk Prediction

## Week 1-2 Objectives âœ… FULLY ACHIEVED
- Complete data understanding and exploratory data analysis
- Implement comprehensive data preprocessing pipeline
- Train and evaluate 5 baseline machine learning models
- Conduct thorough error analysis with clinical context
- Establish project infrastructure and documentation

## Major Accomplishments

### ðŸŽ¯ **Dataset & Analysis Pipeline** âœ…
- **Dataset:** 100,000 diabetes samples with 28 clinical and demographic features
- **Data Split:** 70K training, 15K validation, 15K test (stratified)
- **Quality:** Zero missing values, proper feature engineering completed
- **EDA:** Comprehensive exploratory analysis in `01_exploratory_analysis.ipynb`
- **Processing:** Professional preprocessing pipeline in `02_data_processing.ipynb`

### ðŸ¤– **Baseline Model Results** âœ…
| Model | ROC-AUC | Accuracy | Training Time | Key Strength |
|-------|---------|----------|---------------|--------------|
| **PyTorch Neural Network** | **0.9436** | 0.9171 | 18.7s | Best overall performance |
| Random Forest | 0.9415 | 0.9197 | 1.2s | Fewest false alarms (6) |
| XGBoost | 0.9402 | 0.9193 | 0.3s | Fastest training |
| SVM | 0.9353 | 0.8931 | 398s | Good precision |
| Logistic Regression | 0.9346 | 0.8614 | 0.1s | Fewest missed cases (955) |

### ðŸ” **Clinical Error Analysis** âœ…
- **Comprehensive Analysis:** `04_error_analysis.ipynb` with clinical decision context
- **Key Finding:** Optimal screening threshold = 0.1 (vs default 0.5)
- **Clinical Impact:** All models show 93.4%+ ROC-AUC (excellent performance)
- **Error Patterns:** HbA1c and glucose_fasting are primary misclassification drivers
- **Trade-offs:** Random Forest minimizes false alarms, Logistic Regression minimizes missed cases

### ðŸ“Š **Deliverables Created** âœ…
1. **Notebooks:** 4 comprehensive Jupyter notebooks (EDA, preprocessing, modeling, error analysis)
2. **Models:** 5 trained baseline models saved with full metrics
3. **Analysis Files:** 100+ analysis outputs including:
   - Confusion matrices for all models
   - Classification reports with clinical context
   - Misclassification analysis by demographics
   - ROC curves comparison
   - Clinical decision threshold optimization
4. **Documentation:** Updated project structure and progress tracking

## Key Technical Achievements

### ðŸš€ **PyTorch Neural Network Optimization**
- **Mac M1/M2 Compatibility:** Successfully implemented MPS acceleration
- **Performance:** Reduced training time from 8+ hours to 18.7 seconds
- **Architecture:** Optimized 3-layer network with dropout and batch normalization
- **Results:** Best ROC-AUC (0.9436) with excellent calibration

### ðŸ“ˆ **Clinical Decision Optimization**
- **Threshold Analysis:** Comprehensive evaluation of decision boundaries
- **Clinical Cost Model:** Weighted false negatives (10x) vs false positives (1x)
- **Recommendation:** Lower threshold to 0.1 for maximum clinical benefit
- **Impact:** +24,000 clinical value units improvement for neural network

## Challenges Overcome
1. **PyTorch Training Issues:** Resolved Mac M1/M2 hanging with MPS optimization
2. **Model Integration:** Successfully integrated 5 different model types
3. **Clinical Context:** Translated ML metrics into healthcare decision scenarios
4. **Scale Management:** Efficiently processed 100K samples across all models

## Week 3-4 Strategic Priorities

### ðŸŽ¯ **Immediate Focus Areas**
1. **Hyperparameter Optimization:** RandomizedSearchCV with clinical cost functions
2. **Ensemble Methods:** Combine Random Forest precision with Neural Network recall
3. **Clinical Validation:** Test optimized thresholds on held-out test set
4. **Literature Review:** Focus on diabetes screening ML and decision thresholds

### ðŸ“‹ **Success Metrics for Next Sprint**
- ROC-AUC improvement > 0.005 (target: >0.9486)
- False negative rate < 10% (clinical priority)
- Maintain false positive rate < 5%
- Clinical value score improvement > 50 units

## Risk Assessment - REDUCED FROM INITIAL
- **Low Risk:** Technical implementation (proven successful)
- **Low Risk:** Data quality (excellent dataset confirmed)
- **Medium Risk:** Clinical validation (requires domain expertise)
- **Low Risk:** Timeline adherence (ahead of schedule)

## Action Items for Week 3-4
| Task | Owner | Due Date | Priority |
|------|-------|----------|----------|
| Hyperparameter tuning implementation | Peter | Dec 23 | High |
| Ensemble model development | Peter | Dec 26 | High |
| Test set validation | Peter | Dec 29 | Medium |
| Literature review update | Peter | Jan 2 | Medium |

## Meeting Notes & Decisions
- **Exceeded Expectations:** All Week 1-2 deliverables completed with high quality
- **Technical Success:** Mac M1/M2 optimization breakthrough enables faster iteration
- **Clinical Focus:** Error analysis reveals clear optimization opportunities
- **Next Phase:** Shift focus to ensemble methods and clinical validation

---
**Project Status:** ðŸŸ¢ ON TRACK - Ahead of Schedule  
**Next Meeting:** January 2, 2026 (Week 3-4 Review)  
**Overall Progress:** Week 1-2 Complete âœ… | Week 3-4 Ready ðŸš€